

Events

Event

ACI 14th Annual Summit on Biosimilars & Innovator Biologics


When: June 27, 2023

People: Aziz Burgy, Jason Murata

Related People



Aziz Burgy



Jason Murata

Related Services

Intellectual Property

On June 27, Axinn partners Aziz Burgy and Jason Murata spoke at American Conference Institute's 14th Summit on Biosimilars & Innovator Biologics held June 27-28 in Boston.

Aziz spoke on a panel entitled, "Preparing for Biosimilar Carve Outs: Will Skinny Labelling Work for Biosimilars?" Panelists discussed:

- Balancing the cost savings resulting from lowered litigation risk with the loss of market opportunities resulting from carve-out.
- How the skinny label regime will work with biosimilar products that have interchangeable designation.
- Potential liability faced by insurers for placement of skinny label on formularies.
- Whether carve-outs will add to the perception that the biosimilar product is different than and not as effective as the reference product.

Jason moderated a panel entitled, "Hedging Your Bets Ahead of Amgen v Sanofi: Anticipating how the Supreme Court's Enablement Ruling will Affect Biologic Patent Portfolio Strategies." Panelists discussed:

- Alternate strategies for drafting enforceable claims.
- Implementing new strategies for drafting enforceable claims in view of the Supreme Court's decision.
- The nuances between written description and enablement.
- Reconciling whether written description is met when the specification discloses formulas.

To subscribe to our publications, [click here](#).

